Brain Tissue Segmentation and Atrophy Measurement Automation

This workflow automates the quantification of grey matter, white matter, and cerebrospinal fluid from serial MRI scans, eliminating the manual, hours-long contouring and measurement process per study. For neurology departments and clinical trials, the operational upside is a 60-70% reduction in analysis time per patient, standardizing measurements across large populations and enabling precise, longitudinal tracking of disease progression for conditions like Alzheimer's and multiple sclerosis. The architecture must integrate with PACS for DICOM ingestion, orchestrate specialized segmentation models, and feed quantified volumes into neurology reporting or clinical trial EDC systems.

Implementation requires a pipeline built on frameworks like MONAI or nnU-Net, deployed within a hospital's secure AI inference environment. The orchestrator, potentially using LangGraph, manages model selection, post-processing, and the fusion of tissue volumes with regional parcellation data. Critical controls include automated quality checks on incoming scans, confidence scoring to route uncertain segmentations for human review, and immutable audit logs of all measurements and overrides for clinical governance and regulatory compliance in longitudinal studies.

This workflow automates a critical bottleneck in neurology: the manual, time-consuming segmentation and volumetric analysis of serial brain MRIs. By implementing a custom orchestration pipeline, hospitals and clinical research organizations can standardize measurements across their patient population, reducing radiologist contouring time by 60-70% per study. The operational upside comes from faster report turnaround, consistent quantitative data for clinical trials, and the ability to track subtle progression changes with high precision, directly impacting treatment decisions and trial endpoint validation.

Implementation requires tight integration with hospital PACS, neurology EMRs like Epic or Cerner, and a rules engine for routing exceptions. The orchestrator, built on frameworks like LangGraph, manages DICOM ingestion, dispatches to specialized containerized models, and enforces quality gates. Critical controls include confidence-based escalation to a Nuance PowerScribe-like review station, comprehensive audit logging for all overrides, and continuous performance monitoring against a gold-standard dataset to detect model drift, ensuring the pipeline remains clinically reliable and audit-ready for regulated use.

The operational upside comes from automating the manual, time-consuming process of contouring grey matter, white matter, and CSF on serial MRIs. A custom workflow standardizes measurements, reduces inter-reader variability by over 70%, and frees neurologists from repetitive volumetric analysis, redirecting 15-20 hours per week toward complex case review and patient care. The architecture integrates directly with PACS for DICOM ingestion and the neurology module of the EHR (e.g., Epic, Cerner) for reporting, ensuring measurements are actionable within clinical workflows.

Implementation requires a phased, safety-first approach. Phase 1 runs the pipeline in 'silent mode,' logging outputs against gold-standard reads to establish baseline accuracy. Phase 2 introduces the system as an assistive tool, generating draft quantitative reports in the EHR for physician sign-off. The final phase activates intelligent worklist prioritization in the RIS, routing cases with significant interval atrophy to the top of the queue. Each phase is governed by a confidence-scoring agent that flags low-certainty segmentations for mandatory human review, embedding clinical safety into the automation layer.

A robust governance architecture is non-negotiable for clinical AI. The workflow must integrate with the hospital's Identity and Access Management (IAM) system to enforce role-based access control, ensuring only credentialed neurologists and radiologists can approve final atrophy reports. All model inferences require an immutable audit trail in a system like Datadog or Azure Monitor, logging the input DICOM series, segmentation model version, confidence scores, and any subsequent physician overrides. This creates a defensible record for clinical governance and model performance monitoring, directly supporting FDA 510(k) or CE Mark submissions.

Rollout should follow a phased, risk-managed approach. Phase 1 is a silent pilot: the pipeline runs in parallel with manual processes, generating reports that are validated but not used clinically, establishing baseline accuracy and exception rates. Phase 2 introduces assisted reporting for a single neurology subspecialty (e.g., MS clinic), with all outputs requiring mandatory physician sign-off in the EMR before release. Phase 3 expands to full autonomous operation for stable, follow-up cases where confidence scores are high, while complex or low-confidence studies are automatically routed to the human-in-the-loop review queue. This controlled scaling mitigates risk while delivering incremental operational upside in measurement standardization and report turnaround time.